Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ANDROMEDA Strain: Full Data Published From Multaq Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Details show death rates that led to Sanofi study's halt.
Advertisement

Related Content

Sanofi Halts Multaq Trial Early Due To Cardiac Events
Sanofi Halts Multaq Trial Early Due To Cardiac Events
Sanofi Halts Multaq Trial Early Due To Cardiac Events
Multaq Panel Resolves Mortality Concerns, Looks At Restricted Claims
FDA Not Forgetting Sanofi’s Previous Failed Trial In New Multaq Review
Sanofi-Aventis Gets Priority Review For Second-Generation Atrial Fib Drug
Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter
Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter
Astellas/Cardiome Reports Positive Kynapid Phase III Study
Sanofi Dronedarone Re-Filing Anticipated In 2008 After FDA “Non Approvable” Letter

Topics

Advertisement
UsernamePublicRestriction

Register

PS067937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel